Onxeo: Publication of the 2021 Annual Financial Report

PARIS–(BUSINESS WIRE)–Regulatory news:

Onxeo SA (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereinafter “Onxeo“or the”Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR), today announced the release of the Company’s 2020 Annual Financial Report.

The 2021 annual financial report is made available to the public on the Company’s website.

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after area of ​​tumor damage response. DNA (DDR). The Company is focused on bringing novel or innovative compounds from early-stage translational research to clinical proof of concept, an attractive value-creating inflection point for potential partners.

Plato is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and expands the Company’s product portfolio.

AsiDNA, platON’s first compound, is a highly differentiated clinical-stage first-in-call candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of several DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor-damaging agents. tumor DNA such as radio-chemotherapy. AsiDNA is currently undergoing combined clinical trials in hard-to-treat solid tumors.

OX401 is a new drug candidate from platON, designed to be a next-generation PARP inhibitor acting both on the DNA damage response and on the activation of the immune response, without inducing resistance. OX401 is currently being optimized and undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For more information, please visit www.onxeo.com.

Forward-looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. These statements involve certain known and unknown risks, uncertainties and other factors, which could cause Onxeo’s actual results, financial condition, performance or achievements to be materially different from any future results, performance or achievements expressed or implied. implied by these forward-looking statements. . Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of the risks and uncertainties that could cause Onxeo’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent reference of the Company or in any other periodic financial report and in any other press release, which are available free of charge on the Company’s Group websites (www.onxeo.com) and/or the AMF (www.amf-france.org).

Jacob L. Thornton